Trial Profile
The Risk of Cardiovascular Events Among HIV Patients Initiating Efavirenz-containing Versus Efavirenz-free Antiretroviral Regimens
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Sep 2015
Price :
$35
*
At a glance
- Drugs Efavirenz (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 22 Jul 2015 Results presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.
- 29 Apr 2015 New trial record